UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15

Bone marrow transplantation (Basingstoke), 2022-05, Vol.57 (5), p.824-826

2022

Volltextzugriff (PDF)

Case Report: Large Granular Lymphocyte Leukemia (LGLL)-A Case Series of Challenging Presentations

Frontiers in oncology, 2022-01, Vol.11, p.775313

2022

Volltextzugriff (PDF)

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible

Frontiers in oncology, 2020-09, Vol.10

2020

Volltextzugriff (PDF)

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Blood, 2023-11, Vol.142 (Supplement 1), p.3521-3521

2023

Volltextzugriff (PDF)

Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed Therapies

Blood, 2022-11, Vol.140 (Supplement 1), p.12492-12493

2022

Volltextzugriff (PDF)

Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia

Cancers, 2019-10, Vol.11 (11), p.1625

2019

Volltextzugriff (PDF)

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.1008-1008

2023

Volltextzugriff (PDF)

Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy

Current treatment options in oncology, 2020-01, Vol.21 (1), p.8-8, Article 8

2020

Volltextzugriff (PDF)

Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.4207-4208

2022

Volltextzugriff (PDF)

Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation

Clinical lymphoma, myeloma and leukemia, 2021-07, Vol.21 (7), p.e579-e582

2021

Volltextzugriff (PDF)

P-019 Cytotoxic CD4+ T cells are major drivers of side effects and response after chimeric antigen receptor T cells against BCMA

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S51-S51

2024

Volltextzugriff (PDF)

Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24 (9), p.e277-e282

2024

Volltextzugriff (PDF)

P-105 PET/CT Has Prognostic Significance for CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S103-S104

2024

Volltextzugriff (PDF)

OA-04 Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S3-S3

2023

Volltextzugriff (PDF)

P-009 Cellular dynamics following CAR T cell therapy are associated with response, resistance and cytokine release syndrome in relapsed/refractory myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S37-S38

2023

Volltextzugriff (PDF)

Elucidating functional heterogeneity in hematopoietic progenitor cells: A combined experimental and modeling approach

Experimental hematology, 2014-09, Vol.42 (9), p.826-837.e17

2014

Volltextzugriff (PDF)

Characterizing functional heterogeneity in hematopoietic progenitor cell cultures: a combined experimental and modeling approach

Experimental hematology, 2013-08, Vol.41 (8), p.S66-S66

2013

Volltextzugriff (PDF)

Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia

Leukemia & lymphoma, 2012-08, Vol.53 (8), p.1569-1576

2012

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library E-Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(33)
Berichte
(5)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15

Case Report: Large Granular Lymphocyte Leukemia (LGLL)-A Case Series of Challenging Presentations

Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible

P1415: CELLULAR DYNAMICS IN RESPONDERS AND NON‐RESPONDERS AFTER THE TREATMENT OF PATIENTS WITH AGGRESSIVE B‐ZELL LYMPHOMAS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma

Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed Therapies

Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy

Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia

Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes - No Association of Clonal Hematopoiesis (CH) with Manufacturing Success

Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation

P-019 Cytotoxic CD4+ T cells are major drivers of side effects and response after chimeric antigen receptor T cells against BCMA

Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma

P-105 PET/CT Has Prognostic Significance for CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

OA-04 Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

P-009 Cellular dynamics following CAR T cell therapy are associated with response, resistance and cytokine release syndrome in relapsed/refractory myeloma

Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma

Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

Elucidating functional heterogeneity in hematopoietic progenitor cells: A combined experimental and modeling approach

Characterizing functional heterogeneity in hematopoietic progenitor cell cultures: a combined experimental and modeling approach

Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia

Aktive Filter

Suchergebnisse filtern